Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Themis Leverages Measles Vector Platform In Collaboration With Merck & Co.

Executive Summary

In its first big pharma deal, Austrian biotech will develop experimental vaccines for Merck against an undisclosed target. Innovent licenses Chinese rights to Lilly diabetes candidate, while Novartis gets option to Iconic’s preclinical ophthalmology program.

You may also be interested in...



Deal Watch: Roche And Vividion Will Investigate E3 Ligases In Cancer, Immunology

Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK

Glenmark On Course For Xolair Biosimilar Deal, US Capital Raise For Innovation

Glenmark appears close to sewing up a deal for its biosimilar version of Novartis/Genentech's Xolair amid the firm's ongoing focus on partnering out some key assets. It also expects to kick off plans to raise capital in the US for its innovation business in Q4 of fiscal 2019-20.

Genexine, ToolGen Merger Collapses Amid Stock Drops, But Collaboration Still Planned

The planned merger between Genexine and ToolGen, which was poised to create a major Korean biotech entity, has collapsed amid recent generally weak investor sentiment over the sector. But the two sides will maintain their collaborations for new drug development going forward, with a focus on gene and cell therapies.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1130496

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel